Fujifilm Corporation, the parent company of Fujifilm Diosynth Biotechnologies, has announced an additional investment of $1.2 billion to further expand Fujifilm’s Diosynth Biotechnologies biomanufacturing facility in Holly Springs, North Carolina, to bring the total investment in the facility to over $3.2 billion.  

The expansion adds additional large-scale production capacity and will add 8 x 20,000-L mammalian cell-culture bioreactors by 2028, to the already planned 8 x 20,000-L bioreactors for added bulk drug substance capacity as part of the initial investment. The company was already investing $2 billion in the Holly Springs facility.  

Separately, the company announced this week (April 16, 2024) that it plans to restructure its Small-Scale Business Unit globally, which may result in up to 240 employees leaving the company. The affected sites are in Teesside, the UK; College Station, Texas; Raleigh, North Carolina; and Watertown, Massachusetts. 

The company says that its Small-Scale Business Unit has been directly impacted by the short-term challenge of reduced venture capital investment in early-stage research projects, particularly in the cell and gene therapies market.   

Source: Fujifilm Corporation (expansion) and Fujifilm Corporation (restructuring)